Structural Heart Occluders

This channel includes news and new technology innovations about structural heart occluders. These include information of surgical repair and transcatheter closure of PFO, VSD, ASD and LAA. Devices include the Amplatzer and the Gore Helex

Surgeons Use Novel Occluder with a Metal-Free Frame on a Patient with ASD
May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial septal defects (ASD), or opening defect in the wall of the heart that separates the ...
Front Line Medical Technologies Expands Availability of its COBRA-OS
February 18, 2022 – Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of its COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System), as ...
New ASE Guideline Outlines Acquisition of Essential Transesophaegal Echo Images in Structural Heart Prior to Intervention
January 17, 2022 – As the increasing number of structural heart interventions are assisted by real-time imaging guidance, interventional echocardiography is being recognized as a subspecialty ...
First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes
November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage (LAA) transcatheter occluder with the new generation Boston Scientific Watchman ...

atHeart Medical’s reSept ASD Occluder is designed to preserve patients’ future transseptal treatment options

News | Structural Heart Occluders

Promising Long- and Short-term Clinical Data Show Potential of First ASD Occluder with a Bioresorbable, Metal-free Frame

June 20, 2024 — atHeart Medical, a medical device company establishing a new standard of care for atrial septal defects ...

June 20, 2024

Illustration for the deployment and shaping process of the occluder.

News | Structural Heart Occluders

Transcatheter Closure of Perimembranous Ventricular Septal Defect Using a Novel Fully Bioabsorbable Occluder: Multicenter Randomized Controlled Trial

July 14, 2023 — In recent years, transcatheter intervention techniques have emerged as a promising alternative for the ...

July 14, 2023

Data from "Real-Time Atrial Appendage Assessment for LAAO-CLAAS Device Selection: Angiography vs TEE" was presented at Cardiovascular Research Technologies Conference (CRT)

News | Left Atrial Appendage (LAA) Occluders

Study Demonstrates Successful Device Size Selection When Assessing Left Atrial Appendage by Angiography Compared to TEE

February 27, 2023 — Conformal Medical, Inc. announced today the results from the CONFORMAL Early Feasibility Study (EFS) ...

February 27, 2023

News | Structural Heart Occluders

Surgeons Use Novel Occluder with a Metal-Free Frame on a Patient with ASD

May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial ...

May 05, 2022

Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of its COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System), as U.S. and Canadian hospitals continue to implement the life-saving aortic occlusion device during various surgical and emergency cases.

News | Endovascular Aortic Repair

Front Line Medical Technologies Expands Availability of its COBRA-OS

February 18, 2022 – Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of ...

February 18, 2022

The ASE released new guidelines for pre-procedural structural heart echo imaging assessments. This image showing the aortic and mitral valves in life-like TrueView rendering is from a Philips Epiq CV version 9.0 system.

News | Structural Heart

New ASE Guideline Outlines Acquisition of Essential Transesophaegal Echo Images in Structural Heart Prior to Intervention

January 17, 2022 – As the increasing number of structural heart interventions are assisted by real-time imaging guidance ...

January 17, 2022

The two FDA-cleared transcatheter LAA occlusion devices on the U.S. market were compared in the SWISS-APERO and SEAL FLX trials presented at TCT 2021. Left is the Abbott Amulet device, right is the newest generation Watchman FLX device.

News | Left Atrial Appendage (LAA) Occluders

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

November 08, 2021

The Abbott Amplatzer Talisman PFO Occlusion System is designed to treat people with a patent foramen ovale (PFO). The small opening between the upper chambers of the heart can increase the risk of recurrent ischemic stroke.

News | Structural Heart Occluders

FDA Clears Abbott Amplatzer Talisman PFO Occluder

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

October 04, 2021

Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being deployed into the LAA. FDA is concerned about higher rates of LAA occlusion complications in women compared to men, prompting the FDA to send a letter to providers warning them on possible poor outcomes.

Feature | Left Atrial Appendage (LAA) Occluders

FDA Concerned About Higher Rates of LAA Occlusion Complications in Women

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

September 27, 2021

The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Feature | Structural Heart Occluders | By Dave Fornell, Editor

FDA Clears Abbott Portico TAVR System to Treat Aortic Valve Disease

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

September 20, 2021

News | Left Atrial Appendage (LAA) Occluders

Abbott Amplatzer Amulet LAA Occluder Offers Superior Closure Compared to Watchman

August 31, 2021 — Late-breaking data from a head-to-head clinical trial of the Amulet Left Atrial Appendage (LAA) ...

August 31, 2021

The Abbott Amplatzer Amulet left atrial appendage (LAA) transcatheter occlusion device. It received FDA clearance in August 2021. #LAA

News | Left Atrial Appendage (LAA) Occluders

FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation

August 16, 2021 — The U.S. Food and Drug Administration (FDA) approved Abbott's Amplatzer Amulet Left Atrial Appendage ...

August 16, 2021

CentraCare completed the first structural heart procedure in the world guided by a new 4-D hologram technology developed by EchoPixel. The augmented reality technology aims to reduce reduce procedure time, improve accuracy of the procedure, and reduce risk of complications.

Feature | Virtual and Augmented Reality

First 4D Hologram Guided Structural Heart Procedure Performed for LAA Occlusion

June 28, 2021 — CentraCare, one of the largest health systems in Minnesota, successfully completed the first structural ...

June 28, 2021

Videos | Congenital Heart

VIDEO: Advances in Congenital Heart Therapy Technologies

Tom Jones, M.D., director, cardiac catheterization laboratories, Seattle Children’s Hospital, explains some of the new ...

May 26, 2021

The Boston Scientific Watchman device have performed better than expected in real-world patients outside of trials since it was introduced in 2015, according to data from the NCDR LAAO Registry. #ACC21 #ACC2021 #LAA #Watchman

Feature | Left Atrial Appendage (LAA) Occluders

NCDR LAAO Registry Shows Left Atrial Appendage Occlusion Associated With Low Rate of Stroke

May 15, 2021 - Transcatheter left atrial appendage occlusion (LAAO) with a Boston Scientific Watchman device was ...

May 16, 2021